<DOC>
	<DOCNO>NCT00280865</DOCNO>
	<brief_summary>This 12-week randomized , double-blind , multi-center , active-controlled ( open-label pioglitazone ) placebo-controlled study tesaglitazar ( 0.1 , 0.5 , 1 , 2 , 3 mg ) patient type 2 diabetes , adequately control diet lifestyle advice alone run-in period . The study comprise 2-week enrollment period , 4 week placebo single blind run period follow 12-week double blind treatment period 3-week follow-up period</brief_summary>
	<brief_title>GLAD : Dose-Finding , Efficacy , Safety AZ 242 ( Tesaglitazar ) Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Provision write informed consent Men woman 30 80 year age Female patient : postmenopausal surgically sterile Diagnosed type 2 diabetes Cpeptide level &gt; 0.8 ng/mL Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , PPAR g PPAR g agonist . History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level 1.2 mg/dL Received investigational product clinical study within 30 day Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient â€™ safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Tesaglitazar</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>